Pathophysiologic and Transcriptomic Analyses of Viscerotropic Yellow Fever in a Rhesus Macaque Model

PLoS Neglected Tropical Diseases

Volumn 8, Issue 11, 2014, Pages

  Engelmann, Flora ^a   Josset, Laurence ^b   Girke, Thomas ^c   Park, Byung ^d   Barron, Alex ^d   Dewane, Jesse ^e   Hammarlund, Erika ^e   Lewis, Anne ^e   Axthelm, Michael K ^d,e   Slifka, Mark K ^e   Messaoudi, Ilhem ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVER ENZYME; TRANSCRIPTOME; LIVE VACCINE; VIRUS ANTIGEN; YELLOW FEVER VACCINE;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOGENIC SHOCK; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE COURSE; FEMALE; GENE EXPRESSION; HOMEOSTASIS; HOST PATHOGEN INTERACTION; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LIVER INJURY; LYMPHOCYTOPENIA; MICROARRAY ANALYSIS; MULTIPLE ORGAN FAILURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; RHESUS MONKEY; VIRUS TRANSMISSION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS; ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; KIDNEY; LIVER; MONONUCLEAR CELL; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPLEEN; VIROLOGY; YELLOW FEVER VIRUS;

ANIMALS; ANTIGENS, VIRAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMANS; KIDNEY; LEUKOCYTES, MONONUCLEAR; LIVER; LYMPHOPENIA; MACACA MULATTA; MULTIPLE ORGAN FAILURE; NECROSIS; SPLEEN; TRANSCRIPTOME; VACCINES, ATTENUATED; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84920431318     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003295     Document Type: Article

References (64)

1. Russell MN, Cetron MS, Eidex RB, (2006) The US-Certified Yellow Fever Vaccination Center Registry: a tool for travelers, state health departments, and vaccine providers. J Travel Med 13: 48–49.
2. Bryant JE, Holmes EC, Barrett AD, (2007) Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog 3: e75.
3. Tomori O, (2004) Yellow fever: the recurring plague. Crit Rev Clin Lab Sci 41: 391–427.
4. Barrett AD, Higgs S, (2007) Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol 52: 209–229.
5. Paessler S, Walker DH, (2013) Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol 8: 411–440.
6. Gardner CL, Ryman KD, (2010) Yellow fever: a reemerging threat. Clin Lab Med 30: 237–260.
7. Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE, (2007) 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine 25: 2758–2765.
8. Hayes EB, (2007) Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 101: 967–971.
9. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, et al. (2001) Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358: 98–104.
10. Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, et al. (2005) Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23: 3256–3263.
11. Lawrence GL, Burgess MA, Kass RB, (2004) Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell 28: 244–248.
12. Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, et al. (2005) Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 1: 207–214.
13. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, et al. (2008) Adverse event reports following yellow fever vaccination. Vaccine 26: 6077–6082.
14. Sencer D, Langmuir A, Kokko U, (1966) Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. Jama 198: 671–672.
15. Monath TP (2004) Yellow fever vaccine. In: Plotkin S, editor. Vaccines. 4th ed. Philadelphia: W.B. Saunders. pp. 1095–1176.
16. Monath TP, (2012) Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 11: 427–448.
17. Sbrana E, Xiao SY, Popov VL, Newman PC, Tesh RB, (2006) Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values. Am J Trop Med Hyg 74: 1084–1089.
18. Tesh RB, Guzman H, da Rosa AP, Vasconcelos PF, Dias LB, et al. (2001) Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis 183: 1431–1436.
19. Xiao SY, Zhang H, Guzman H, Tesh RB, (2001) Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis 183: 1437–1444.
20. Thibodeaux BA, Garbino NC, Liss NM, Piper J, Blair CD, et al. (2012) A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain. Vaccine 30: 3180–3187.
21. Monath TP, Brinker KR, Chandler FW, Kemp GE, Cropp CB, (1981) Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am J Trop Med Hyg 30: 431–443.
22. Almeida MABd, Santos Ed, Cardoso JdC, Fonseca DFd, Noll CA, et al. (2012) Yellow fever outbreak affecting Alouatta populations in southern Brazil (Rio Grande do Sul State), 2008–2009. American Journal of Primatology 74: 68–76.
23. Hammarlund E, Amanna IJ, Dubois ME, Barron A, Engelmann F, et al. (2012) A flow cytometry-based assay for quantifying non-plaque forming strains of yellow Fever virus. PLoS One 7: e41707.
24. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
25. Bolstad BM, Irizarry RA, Gautier L, Wu Z (2005) Preprocessing High-density Oligonucleotide Arrays In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S, editors. Bioinformatics and Computational Biology Solutions Using R and Bioconductor: Springer.
26. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
27. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B (Methodological) 57: 289–300.
28. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25–29.
29. Josset L, Engelmann F, Haberthur K, Kelly S, Park B, et al. (2012) Increased Viral Loads and Exacerbated Innate Host Responses in Aged Macaques Infected with the 2009 Pandemic H1N1 Influenza A Virus. J Virol 86: 11115–11127.
30. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545–15550.
31. Todd EM, Deady LE, Morley SC, (2013) Intrinsic T- and B-cell defects impair T-cell-dependent antibody responses in mice lacking the actin-bundling protein L-plastin. Eur J Immunol 43: 1735–1744.
32. Todd EM, Deady LE, Morley SC, (2011) The actin-bundling protein L-plastin is essential for marginal zone B cell development. J Immunol 187: 3015–3025.
33. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, et al. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175–179.
34. Schroder WA, Major L, Suhrbier A, (2011) The role of SerpinB2 in immunity. Crit Rev Immunol 31: 15–30.
35. Pasero C, Olive D, (2013) Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity. Immunol Lett 151: 71–75.
36. Tateyama M, Oyaizu N, McCloskey TW, Than S, Pahwa S, (2000) CD4 T lymphocytes are primed to express Fas ligand by CD4 cross-linking and to contribute to CD8 T-cell apoptosis via Fas/FasL death signaling pathway. Blood 96: 195–202.
37. Mirenda V, Jarmin SJ, David R, Dyson J, Scott D, et al. (2007) Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28. Blood 109: 2968–2977.
38. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, et al. (2004) RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res 64: 8688–8693.
39. Falzarano D, Feldmann H, (2013) Vaccines for viral hemorrhagic fevers–progress and shortcomings. Curr Opin Virol 3: 343–351.
40. Stokes A, Bauer JH, Hudson NP, (2001) The transmission of yellow fever to Macacus rhesus. 1928. Rev Med Virol 11: 141–148.
41. Fox JP, Penna HA, (1943) Behavior of 17D yellow fever virus in rhesus monkeys: relation to substrain, dose and neural or extraneural inoculation. Am J Hyg 38: 152.
42. Groot H, (1962) Serological reactions in Rhesus monkeys inoculated with the 17D strain of yellow fever virus. Bull World Health Organ 27: 709–715.
43. Mason RA, Tauraso NM, Spertzel RO, Ginn RK, (1973) Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25: 538–544.
44. Bauer JH, (1931) Some Characteristics of Yellow Fever Virus. Am J Trop Med 11: 337–378.
45. ter Meulen J, Sakho M, Koulemou K, Magassouba NF, Bah A, et al. (2004) Activation of the Cytokine Network and Unfavorable Outcome in Patients with Yellow Fever. Journal of Infectious Diseases 190: 1821–1827.
46. Quaresma JA, Pagliari C, Medeiros DB, Duarte MI, Vasconcelos PF, (2013) Immunity and immune response, pathology and pathologic changes: progress and challenges in the immunopathology of yellow fever. Rev Med Virol 23: 305–318.
47. Quaresma JA, Barros VL, Pagliari C, Fernandes ER, Guedes F, et al. (2006) Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity. Virology 345: 22–30.
48. Quaresma JA, Barros VL, Pagliari C, Fernandes ER, Andrade HF, Jret al. (2007) Hepatocyte lesions and cellular immune response in yellow fever infection. Trans R Soc Trop Med Hyg 101: 161–168.
49. Quaresma JA, Barros VL, Fernandes ER, Pagliari C, Guedes F, et al. (2006) Immunohistochemical examination of the role of Fas ligand and lymphocytes in the pathogenesis of human liver yellow fever. Virus Res 116: 91–97.
50. Aleksandrowicz P, Wolf K, Falzarano D, Feldmann H, Seebach J, et al. (2008) Viral haemorrhagic fever and vascular alterations. Hamostaseologie 28: 77–84.
51. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM, (2010) Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 4: pii: e837 doi:10.1371/journal.pntd.0000837
52. Woodson SE, Freiberg AN, Holbrook MR, (2011) Differential cytokine responses from primary human Kupffer cells following infection with wild-type or vaccine strain yellow fever virus. Virology 412: 188–195.
53. Belsher JL, Gay P, Brinton M, DellaValla J, Ridenour R, et al. (2007) Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 25: 8480–8485.
54. Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, et al. (2008) Case of yellow fever vaccine–associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 198: 500–507.
55. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116–125.
56. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, et al. (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119–3131.
57. Mattijssen S, Pruijn GJ, (2012) Viperin, a key player in the antiviral response. Microbes Infect 14: 419–426.
58. Khaiboullina SF, Rizvanov AA, Holbrook MR, St Jeor S, (2005) Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression. Virology 342: 167–176.
59. Colpitts TM, Cox J, Vanlandingham DL, Feitosa FM, Cheng G, et al. (2011) Alterations in the Aedes aegypti transcriptome during infection with West Nile, dengue and yellow fever viruses. PLoS Pathog 7: e1002189.
60. Prasad AS, (2013) Discovery of human zinc deficiency: its impact on human health and disease. Adv Nutr 4: 176–190.
61. Ibs KH, Rink L, (2003) Zinc-altered immune function. J Nutr 133: 1452S–1456S.
62. Fraker PJ, King LE, (2004) Reprogramming of the immune system during zinc deficiency. Annu Rev Nutr 24: 277–298.
63. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM, (2004) The NS5A protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem 279: 48576–48587.
64. Stempniak M, Hostomska Z, Nodes BR, Hostomsky Z, (1997) The NS3 proteinase domain of hepatitis C virus is a zinc-containing enzyme. J Virol 71: 2881–2886.